Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
Excerpt from the Press Release:
LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone and Mineral Research 2021 Annual Meeting. These results demonstrated that repeat administration of AZP-3601 to healthy volunteers induced a rapid, dose-dependent increase in serum calcium levels that was sustained and stable over the treatment period. In addition, no increase in urinary calcium excretion was observed, and bone biomarkers were unchanged, as was expected based on the unique mechanism of action of AZP-3601 and its short pharmacokinetic half-life.
These data will be presented in a poster at the American Society for Bone and Mineral Research 2021 Annual Meeting, also available on the Amolyt Pharma website here. The company will host a key opinion leader (KOL) webinar to discuss these results in more detail today, October 1, 2021 at 10:00am ET.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?